StockData

Insight Molecular Diagnostics vs Scinai Immunotherapeutics

IMDX and SCNI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IMDX and SCNI compare

Scinai Immunotherapeutics grew revenue faster over the last twelve months (99.2% versus −60.8% for Insight Molecular Diagnostics).

Scinai Immunotherapeutics keeps more of each dollar of sales as profit, with a net margin of −634% compared with −2956% at Insight Molecular Diagnostics.

Insight Molecular Diagnostics scores higher on the StockData Score (7 against 6 for Scinai Immunotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIMDXSCNI
Size and price
Market cap$58.2M–
Share price$1.78$0.372
Change, 1 year−75.9%−96.2%
Change, 5 years−96.3%−100.0%
Beta (5Y)2.661.20
Employees5845
StockData Score
Total score7 (better)6
Valuation score00
Growth score11
Performance score1 (better)0
Health score55
Dividend score00
Valuation
P/S34.9×–
FCF yield−53.2%–
Growth
Revenue growth (TTM)−60.8%99.2% (better)
Revenue growth, 5Y average27.2%–
Net income growth (TTM)–−273%
Profitability
Gross margin48.3% (better)−202%
Operating margin−3012%−575% (better)
Net margin−2956%−634% (better)
FCF margin−1856%−462% (better)
Return on equity–−84.8%
Return on invested capital–−74.7%
Financial health
Debt / equity–0.00
Current ratio2.00 (better)1.56
Altman Z-score−24.27–
Piotroski F-score4 (better)3
Dividends and buybacks
Buyback yield−44.7%–
Shareholder yield−44.7%–
Ownership
Held by institutions56.4%–
Held by insiders81.6%7.4%
Insider net buying, 12 months$5.7M–
Short interest, % of float17.0%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.